Our Work in Neurology

Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the multiple sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category as the increased risk tolerance and the expanding number of therapies evolves the treatment strategies for all forms of MS.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Multiple Sclerosis, Rare Neurological Diseases

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.

RECENT PUBLICATIONS

Genentech’s Ocrevus Begins to Move the Needle on the Treatment Rate for Primary Progressive Multiple Sclerosis but May Not Be the Only Disease-Modifying Therapy in Play – March 13, 2018
>VIEW ARTICLE

Use of Monoclonal Antibody Disease-Modifying Therapies on the Rise in Multiple Sclerosis, Fueled Largely by the Introduction of Genentech’s Ocrevus – January 10, 2018
>VIEW ARTICLE

With Ocrevus Uptake in Primary Progressive Multiple Sclerosis a Relative Lock, Genentech and US Neurologists are Increasingly Focused on Ocrevus Positioning in Relapsing Forms of Multiple Sclerosis – December 7, 2017
>VIEW ARTICLE

UPCOMING CONFERENCES

2018 CMSC Annual Meeting
>LEARN MORE